What is the price-to-earnings ratio of Novocure?
The price-earnings ratio of Novocure is currently 4.29.
Novocure P/S 2025
Novocure P/S
4.29
Ticker
NVCR
ISIN
JE00BYSS4X48
WKN
A140ML
As of Jan 30, 2025, Novocure's P/S ratio stood at 4.29, a 2.88% change from the 4.17 P/S ratio recorded in the previous year.
The Novocure P/S history
Novocure Aktienanalyse
What does Novocure do?
Novocure Ltd. is a global scientific-based company that was founded in Israel in 2000. Its focus was originally on researching and developing tumor therapies. Since then, Novocure has become one of the leading companies in cancer research and treatment, specializing in the development of innovative cancer therapies. The business model of Novocure is based on developing powerful and innovative treatment methods for a variety of cancer types, including brain, pancreatic, prostate, and lung cancer. The company is committed to developing new cancer treatments that improve the lives of patients and meet their needs. Novocure also offers a wide range of products, including several treatment options based on the use of electric fields. These electric fields can specifically target the tumor and inhibit cell division without damaging the surrounding healthy tissue. This innovative technology is also called "tumor therapeutic fields" (TTF). TTF is a non-invasive procedure that is able to destroy cancer cells and inhibit the growth of cancer cells using targeted radio waves. The company also has its own research and development department dedicated to the development of innovative cancer therapies. In collaboration with numerous leading medical experts and researchers worldwide, Novocure advances cancer treatment research and development, striving to improve the treatment of cancer patients worldwide. Novocure operates three main divisions: Onco-Support, Onco-Centers, and Medical Research. The Onco-Support division offers specialized services to patients, such as training on the use of TTF devices, assistance with insurance issues, facilitating access to TTF devices, and help with setting up TTF devices. The Onco-Centers division operates various clinics specialized in the treatment of skin and brain cancer. Here, patients can benefit from the use of TTF devices and receive this therapy from experienced specialists. The Onco-Centers also provide tailored support and counseling for the needs of patients. The Medical Research division of the company also conducts research and development activities in the field of cancer therapies. Here, new therapies and procedures for cancer treatment are explored and developed, with a particular focus on the application of TTF devices. The goal of this research is to develop innovative cancer treatments that improve the lives of cancer patients and give them hope for a better future. Overall, Novocure Ltd. is an innovative and customer-oriented company dedicated to the treatment of cancer patients. The company invests heavily in research and development to develop innovative therapies and products that meet the high needs of cancer patients. The use of TTF technology is a significant step in cancer treatment, and Novocure Ltd. is leading the global development in this regard. Novocure ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Novocure's P/S Ratio
Novocure's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Novocure's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Novocure's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Novocure’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Novocure stock
How has the price-earnings ratio of Novocure changed compared to last year?
The price-to-earnings ratio of Novocure has increased by 2.88% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Novocure high compared to other companies?
Yes, the price-to-earnings ratio of Novocure is high compared to other companies.
How does an increase in the price-earnings ratio of Novocure affect the company?
An increase in the price-earnings ratio of Novocure would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Novocure affect the company?
A decrease in the price-earnings ratio of Novocure would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Novocure?
Some factors that influence the price-earnings ratio of Novocure are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Novocure pay?
Over the past 12 months, Novocure paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novocure is expected to pay a dividend of 0 USD.
What is the dividend yield of Novocure?
The current dividend yield of Novocure is .
When does Novocure pay dividends?
Novocure pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Novocure?
Novocure paid dividends every year for the past 0 years.
What is the dividend of Novocure?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Novocure located?
Novocure is assigned to the 'Health' sector.
Wann musste ich die Aktien von Novocure kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Novocure from 1/30/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/30/2025.
When did Novocure pay the last dividend?
The last dividend was paid out on 1/30/2025.
What was the dividend of Novocure in the year 2024?
In the year 2024, Novocure distributed 0 USD as dividends.
In which currency does Novocure pay out the dividend?
The dividends of Novocure are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Novocure
Our stock analysis for Novocure Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novocure Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.